HANLIKANG (Rituximab Injection)

HANLIKANG (Rituximab Injection)
Product Description

HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has been approved by the NMPA for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis for which the originator rituximab has not been approved in China, benefiting a wider patient population with differentiated strategies.

Read more Show less

Shanghai Henlius Biotech, Inc.

  • CN
  • 2019
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    China
More specifications Fewer specifications
Sales Markets
Show more Show less

Shanghai Henlius Biotech, Inc.

  • CN
  • 2019
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Shanghai Henlius Biotech, Inc. (5)

  • Hyaluronidase

    Product Hyaluronidase

    Henlius has successfully launched a new generation of hyaluronidase products using its exclusive know-how technology, providing innovative pharmaceutical companies with a more efficient, stable and affordable solution for subcutaneous injection.
  • HANBEITAI (Bevacizumab Injection)

    Product HANBEITAI (Bevacizumab Injection)

    HANBEITAI (generic name: bevacizumab), the fourth product independently developed by Henlius, received marketing approval from the National Medical Products Administration (NMPA) in November 2021, and its commercialization in Chinese mainland is handled by the company’s in-house team. As of now, HANBEI...
  • HANDAYUAN (Adalimumab Injection)

    Product HANDAYUAN (Adalimumab Injection)

    Our first product indicated for the treatment of autoimmune diseases. HANDAYUAN (adalimumab injection) was approved by the NMPA in December 2020. It is indicated for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, uveitis, polyarticular juvenile idiopathic arthritis,  pediatric plaque ...
  • HANQUYOU（trastuzumab)

    Product HANQUYOU（trastuzumab)

    HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe) was successfully launched in the U.S., China and Europe, becoming the Chinese mAb biosimilar entering the U.S., the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic bre...
  • HANSIZHUANG (Serplulimab Injection)

    Product HANSIZHUANG (Serplulimab Injection)

    HANSIZHUANG (recombinant humanized anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China and Indonesia. Up to date, 4 indications are approved for marketing, 2 marketing applications a...

Shanghai Henlius Biotech, Inc. resources (1)